TG Therapeutics presented encouraging results from its ENHANCE trial at the American Academy of Neurology 2025 annual meeting. The data demonstrated that a single Day 1 600 mg dose of BRIUMVI was well tolerated by patients.
This positive outcome supports the company's strategic initiative to simplify the BRIUMVI treatment regimen. The goal is to combine the currently approved Day 1 and Day 15 doses into a single 600 mg dose on Day 1.
TG Therapeutics plans to initiate a registration-directed trial to evaluate this streamlined dosing approach, with the ultimate aim of incorporating this more convenient regimen into the BRIUMVI label. This could significantly improve patient experience and enhance the drug's competitive profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.